The Technology Corner: 3 Companies That Could Eradicate Ebola Virus

To the scientific community, the Ebola virus is one of the most noxious pathogens identified to date. To the general population, the virus is dreadful, made especially frightening in pop culture.

Read more »

OneMedRadio: ADVENTRX Hosts First Annual Sickle Cell Disease Therapeutics Conference

September is Sickle Cell Awareness Month, a time when the medical community will gather with the patient population in the hopes of advancing research in this significant unmet medical need. One company, ADVENTRX Pharmaceuticals [NYSE: ANX], is attempting to engage the investor community and the sector’s most promising drug developers through the First Annual Sickle Cell Disease Therapeutics Conference, taking place September 19th, 2012 in New York City.

Read more »

BREAKING: Pluristem Announces Pricing of Public Offering

Pluristem Therapeutics Inc. announced that it has priced a firm commitment underwritten public offering of 8,000,000 units, with each unit consisting of one share of the company’s common stock and one warrant to purchase 0.35 of a share of the company’s common stock, at a purchase price of $4.00 per unit for an aggregate gross offering amount of $32 million. The offering is expected to close on or about September 19, 2012, subject to customary closing conditions.

Read more »

Editor’s Note September 18, 2012

With the end of summer, conference season is upon us! Not OneMedForum, of course, which doesn’t kick off until “Biotech […]

Read more »

Obesity Drug Market: Can Dramatic Returns Outweigh the Risk?

Arena and Vivus’ approval of their obesity drugs — the first such approved in 13 years — have sent shockwaves throughout the industry. With Orexigen’s drug on the way, these have the potential to dramatically alter an entire sub-sector once left for dead. Still, despite positive data and FDA support, these drugs did not reach approval phase without several speed bumps along the way. And more questions are yet to come.

Read more »

BREAKING: Opexa Initiates Late Stage Clinical Study of Tcelna in Patients with Secondary Progressive Multiple Sclerosis (SPMS)

Opexa Therapeutics, Inc. today announced the initiation of a Phase IIb clinical trial of Tcelna™, a novel T-cell therapy for multiple sclerosis (MS), in patients with Secondary Progressive Multiple Sclerosis (SPMS). The therapy is specifically tailored to each patient’s individual disease profile and has demonstrated superior safety and encouraging indications of efficacy in previous clinical studies in MS that included the treatment of SPMS patients.

Read more »

Ann Romney, Michelle Obama Rally For Their Ticket – And The MS Population

With the 2012 Presidential election upon us, healthcare – both as a social service and essential sector of our economy – is once again a main pillar in the heated political debate. Ann Romney and Michelle Obama, both with a direct connection to Multiple Sclerosis, have opened up to campaign supporters in recent months about the effects of this debilitating disease.

Read more »

Bulls, Bears: 3 Promising Stocks in Metastatic Cancer

In this special series, we explore the state of select public companies operating in a particularly intriguing area of life sciences. This week, we look at metastatic cancer, an area of significant unmet need. These companies, including OncoSec Medical, are having success with their innovative approaches to treating metastatic cancer, and are seeing results in their performance int he public markets.

Read more »

The Briefing Room, September 5: Today in Microcap Biotech Stocks

OneMedPlace introduces a new series, “The Briefing Room”, capturing the most important developments in microcap life sciences indexes. This week, we focus on three interesting developments in oncology, and a special bonus!

Read more »